Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).

@article{Ulrich2007BosentanTF,
  title={Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).},
  author={S. Zimmermann Ulrich and Rudolf Speich and Guido Domenighetti and Thomas Geiser and Jean-{\'E}ric. Auteur du texte Aubert and Thierry Rochat and Laurent Huber and Ursula Treder and Mannuel Fischler},
  journal={Swiss medical weekly},
  year={2007},
  volume={137 41-42},
  pages={
          573-80
        }
}
STUDY OBJECTIVES we performed an open-label national study to evaluate the effects of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (CTEPH). PATIENTS AND METHODS fifteen patients with CTEPH not eligible or waiting for surgery were enrolled. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included quality of life (measured by the Minnesota… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Inhaled iloprost

  • H Olschewski, G Simonneau, N Galie
  • monary Hypertension. Respiration
  • 2006

The efficacy of bosen - tan in inoperable chronic thromboembolic pulmonary hypertension : a 1 - year follow - up study

  • HJ Seyfarth, S Hammerschmidt, H Pankau, J Winkler, H Wirtz
  • Eur Respir J
  • 2006

Similar Papers

Loading similar papers…